Compound Detail
CHEMBL1486
TENOFOVIR DISOPROXIL FUMARATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O
Basic Information
| ChEMBL ID | CHEMBL1486 |
| Name | TENOFOVIR DISOPROXIL FUMARATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | VCMJCVGFSROFHV-WZGZYPNHSA-N |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL1538 |
| Active Moiety | CHEMBL258501 |
4
Targets
28
Activities
2
Assay Types
10
PK Parameters
20
Publications
21
Known Names
19
Indications
1
Mechanisms
Molecular Properties
519.5
MW (Da)
3.04
ALogP
15
HBA
1
HBD
185.4
PSA (Ų)
0.23
QED
2
Ro5 Violations
13
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2001 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Human immunodeficiency virus type 1 reverse transcriptase inhibitor | INHIBITOR | Human immunodeficiency virus type 1 reverse transcriptase | ✓ | ✓ |
Indications
Hepatitis B, Chronic Hepatitis B, Chronic HIV Infections HIV Infections Infections Liver Diseases Acquired Immunodeficiency Syndrome Severe Acute Respiratory Syndrome Communicable Diseases Hepatitis D Lipodystrophy Liver Cirrhosis, Biliary Multiple Sclerosis Hepatitis C Hepatitis, Chronic Insulin Resistance Lymphoma Parkinson Disease Tuberculosis
Drug Warnings
Black Box Warning
hepatotoxicity
Black Box Warning
immune system toxicity
Activity Summary
EC50 19 meas. best 8.54
IC50 9 meas. best 7.85
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Human immunodeficiency virus 1 CHEMBL378 | EC50 | 8.54 | 7.3721 | 2.9 | 14 |
| Human immunodeficiency virus 2 CHEMBL380 | EC50 | 8.52 | 8.52 | 3.0 | 2 |
| Hepatitis B virus CHEMBL613497 | EC50 | 7.86 | 6.9333 | 13.8 | 3 |
| Human immunodeficiency virus 1 CHEMBL378 | IC50 | 7.85 | 6.3583 | 14.0 | 6 |
| Hepatitis B virus CHEMBL613497 | IC50 | 6.07 | 5.68 | 850.0 | 2 |
| HepG2 CHEMBL395 | IC50 | 5.64 | 5.64 | 2310.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2148.0 | ng.hr.mL-1 | Rattus norvegicus |
| Cmax | 1345.65 | nM | Rattus norvegicus |
| F | 3.4 | % | Rattus norvegicus |
| T1/2 | 6.14 | hr | Rattus norvegicus |
| t1/2 | - | - | Homo sapiens |
| T1/2 | 27.8 | hr | - |
| t1/2 | - | - | Sus scrofa |
| T1/2 | 0.1667 | hr | Homo sapiens |
| T1/2 | 0.1667 | hr | Homo sapiens |
| Tmax | 0.25 | hr | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine